PubMed:16801510 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T2","span":{"begin":133,"end":144},"obj":"Sentence"},{"id":"T3","span":{"begin":145,"end":210},"obj":"Sentence"},{"id":"T4","span":{"begin":211,"end":282},"obj":"Sentence"},{"id":"T5","span":{"begin":283,"end":476},"obj":"Sentence"},{"id":"T6","span":{"begin":477,"end":485},"obj":"Sentence"},{"id":"T7","span":{"begin":486,"end":718},"obj":"Sentence"},{"id":"T8","span":{"begin":719,"end":886},"obj":"Sentence"},{"id":"T9","span":{"begin":887,"end":1038},"obj":"Sentence"},{"id":"T10","span":{"begin":1039,"end":1047},"obj":"Sentence"},{"id":"T11","span":{"begin":1048,"end":1207},"obj":"Sentence"},{"id":"T12","span":{"begin":1208,"end":1281},"obj":"Sentence"},{"id":"T13","span":{"begin":1282,"end":1412},"obj":"Sentence"},{"id":"T14","span":{"begin":1413,"end":1598},"obj":"Sentence"},{"id":"T15","span":{"begin":1599,"end":1732},"obj":"Sentence"},{"id":"T16","span":{"begin":1733,"end":1860},"obj":"Sentence"},{"id":"T17","span":{"begin":1861,"end":1916},"obj":"Sentence"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-entities","denotations":[{"id":"3032","span":{"begin":13,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3033","span":{"begin":64,"end":73},"obj":"ChemicalEntity"},{"id":"3034","span":{"begin":106,"end":114},"obj":"OrganismTaxon"},{"id":"3035","span":{"begin":158,"end":174},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3036","span":{"begin":211,"end":220},"obj":"ChemicalEntity"},{"id":"3037","span":{"begin":290,"end":299},"obj":"OrganismTaxon"},{"id":"3038","span":{"begin":326,"end":350},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3039","span":{"begin":356,"end":365},"obj":"ChemicalEntity"},{"id":"3040","span":{"begin":593,"end":602},"obj":"ChemicalEntity"},{"id":"3041","span":{"begin":627,"end":636},"obj":"ChemicalEntity"},{"id":"3042","span":{"begin":647,"end":655},"obj":"OrganismTaxon"},{"id":"3043","span":{"begin":734,"end":742},"obj":"OrganismTaxon"},{"id":"3044","span":{"begin":753,"end":762},"obj":"ChemicalEntity"},{"id":"3045","span":{"begin":876,"end":885},"obj":"ChemicalEntity"},{"id":"3046","span":{"begin":902,"end":911},"obj":"ChemicalEntity"},{"id":"3047","span":{"begin":1022,"end":1037},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3048","span":{"begin":1058,"end":1067},"obj":"ChemicalEntity"},{"id":"3049","span":{"begin":1080,"end":1088},"obj":"OrganismTaxon"},{"id":"3050","span":{"begin":1108,"end":1124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3051","span":{"begin":1212,"end":1220},"obj":"OrganismTaxon"},{"id":"3052","span":{"begin":1235,"end":1244},"obj":"ChemicalEntity"},{"id":"3053","span":{"begin":1261,"end":1280},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3054","span":{"begin":1338,"end":1347},"obj":"ChemicalEntity"},{"id":"3055","span":{"begin":1497,"end":1506},"obj":"ChemicalEntity"},{"id":"3056","span":{"begin":1513,"end":1533},"obj":"GeneOrGeneProduct"},{"id":"3057","span":{"begin":1558,"end":1569},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3058","span":{"begin":1612,"end":1636},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3059","span":{"begin":1640,"end":1649},"obj":"ChemicalEntity"},{"id":"3060","span":{"begin":1662,"end":1670},"obj":"OrganismTaxon"},{"id":"3061","span":{"begin":1733,"end":1742},"obj":"ChemicalEntity"},{"id":"3062","span":{"begin":1761,"end":1792},"obj":"ChemicalEntity"},{"id":"3063","span":{"begin":1794,"end":1803},"obj":"ChemicalEntity"},{"id":"3064","span":{"begin":1844,"end":1859},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3065","span":{"begin":1861,"end":1877},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3066","span":{"begin":1906,"end":1915},"obj":"ChemicalEntity"}],"attributes":[{"id":"A7","pred":"db_id","subj":"3038","obj":"MESH:D008133"},{"id":"A18","pred":"db_id","subj":"3049","obj":"NCBITaxon:9606"},{"id":"A1","pred":"db_id","subj":"3032","obj":"MESH:D008133"},{"id":"A23","pred":"db_id","subj":"3054","obj":"MESH:D008691"},{"id":"A27","pred":"db_id","subj":"3058","obj":"MESH:D008133"},{"id":"A35","pred":"db_id","subj":"3066","obj":"MESH:D008691"},{"id":"A4","pred":"db_id","subj":"3035","obj":"MESH:D008133"},{"id":"A30","pred":"db_id","subj":"3061","obj":"MESH:D008691"},{"id":"A14","pred":"db_id","subj":"3045","obj":"MESH:D008691"},{"id":"A21","pred":"db_id","subj":"3052","obj":"MESH:D008691"},{"id":"A29","pred":"db_id","subj":"3060","obj":"NCBITaxon:9606"},{"id":"A17","pred":"db_id","subj":"3048","obj":"MESH:D008691"},{"id":"A25","pred":"db_id","subj":"3056","obj":"NCBIGene:1576"},{"id":"A12","pred":"db_id","subj":"3043","obj":"NCBITaxon:9606"},{"id":"A34","pred":"db_id","subj":"3065","obj":"MESH:D008133"},{"id":"A22","pred":"db_id","subj":"3053","obj":"MESH:D016171"},{"id":"A10","pred":"db_id","subj":"3041","obj":"MESH:D008691"},{"id":"A19","pred":"db_id","subj":"3050","obj":"MESH:D008133"},{"id":"A32","pred":"db_id","subj":"3063","obj":"MESH:D011188"},{"id":"A9","pred":"db_id","subj":"3040","obj":"MESH:D008691"},{"id":"A8","pred":"db_id","subj":"3039","obj":"MESH:D008691"},{"id":"A16","pred":"db_id","subj":"3047","obj":"MESH:D008133"},{"id":"A28","pred":"db_id","subj":"3059","obj":"MESH:D008691"},{"id":"A33","pred":"db_id","subj":"3064","obj":"MESH:D008133"},{"id":"A24","pred":"db_id","subj":"3055","obj":"MESH:D008691"},{"id":"A3","pred":"db_id","subj":"3034","obj":"NCBITaxon:9606"},{"id":"A11","pred":"db_id","subj":"3042","obj":"NCBITaxon:9606"},{"id":"A15","pred":"db_id","subj":"3046","obj":"MESH:D008691"},{"id":"A2","pred":"db_id","subj":"3033","obj":"MESH:D008691"},{"id":"A26","pred":"db_id","subj":"3057","obj":"MESH:D007008"},{"id":"A6","pred":"db_id","subj":"3037","obj":"NCBITaxon:9606"},{"id":"A20","pred":"db_id","subj":"3051","obj":"NCBITaxon:9606"},{"id":"A5","pred":"db_id","subj":"3036","obj":"MESH:D008691"},{"id":"A13","pred":"db_id","subj":"3044","obj":"MESH:D008691"},{"id":"A31","pred":"db_id","subj":"3062","obj":"MESH:D065692"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":13,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":158,"end":174},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":1261,"end":1280},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1861,"end":1877},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0002442"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0002442"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0002442"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005478"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":5,"end":12},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":13,"end":17},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":21,"end":29},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":75,"end":79},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":80,"end":89},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":124,"end":131},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":150,"end":157},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":158,"end":162},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":166,"end":174},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":255,"end":259},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":313,"end":322},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":468,"end":475},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":477,"end":484},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":543,"end":552},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":643,"end":646},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":674,"end":677},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":678,"end":682},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":683,"end":689},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":704,"end":708},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":721,"end":726},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":1010,"end":1021},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":1273,"end":1280},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":1297,"end":1303},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":1369,"end":1373},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1513,"end":1529},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1583,"end":1588},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":1684,"end":1688},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":1698,"end":1702},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":1724,"end":1731},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":1761,"end":1777},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":1782,"end":1792},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":1794,"end":1809},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":1815,"end":1820},"obj":"GeneOrGeneProduct"},{"id":"T34","span":{"begin":1861,"end":1865},"obj":"GeneOrGeneProduct"},{"id":"T35","span":{"begin":1869,"end":1877},"obj":"GeneOrGeneProduct"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":21,"end":29},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":75,"end":79},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":80,"end":89},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":166,"end":174},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":313,"end":322},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":468,"end":475},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":683,"end":689},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":1369,"end":1373},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":1513,"end":1529},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1583,"end":1588},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1761,"end":1777},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":1782,"end":1792},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":1794,"end":1809},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":1815,"end":1820},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":1869,"end":1877},"obj":"GeneOrGeneProduct"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":13,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":158,"end":174},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":188,"end":209},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1022,"end":1037},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1261,"end":1280},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1558,"end":1569},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1844,"end":1859},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1861,"end":1877},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"originalLabel","subj":"T4","obj":"DISEASE"},{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D008133"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"DISEASE"},{"id":"A6","pred":"originalLabel","subj":"T6","obj":"D007008"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D064420"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"D008133"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"D016171"},{"id":"A8","pred":"originalLabel","subj":"T8","obj":"D008133"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":683,"end":689},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":1369,"end":1373},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":1513,"end":1529},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":1761,"end":1777},"obj":"GeneOrGeneProduct"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":13,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":158,"end":174},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":386,"end":396},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1261,"end":1280},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1558,"end":1569},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1861,"end":1877},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1878,"end":1881},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0004938"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0002442"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0002442"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0003019"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0012833"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0005478"},{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0002442"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":13,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":158,"end":174},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":188,"end":209},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":221,"end":245},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":326,"end":350},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1022,"end":1037},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1108,"end":1124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1261,"end":1280},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1558,"end":1569},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1612,"end":1636},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":1844,"end":1859},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":1861,"end":1877},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"ID:","subj":"T4","obj":"DISEASE"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D007008"},{"id":"A11","pred":"ID:","subj":"T11","obj":"DISEASE"},{"id":"A7","pred":"ID:","subj":"T7","obj":"DISEASE"},{"id":"A2","pred":"ID:","subj":"T2","obj":"D008133"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D008133"},{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"},{"id":"A5","pred":"ID:","subj":"T5","obj":"DISEASE"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D064420"},{"id":"A8","pred":"ID:","subj":"T8","obj":"D016171"},{"id":"A10","pred":"ID:","subj":"T10","obj":"DISEASE"},{"id":"A12","pred":"ID:","subj":"T12","obj":"D008133"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":13,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":158,"end":174},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":221,"end":245},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":326,"end":350},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1022,"end":1037},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1108,"end":1124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1261,"end":1280},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1558,"end":1569},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1612,"end":1636},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1844,"end":1859},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":1861,"end":1877},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A10","pred":"#label","subj":"T10","obj":"DISEASE"},{"id":"A11","pred":"#label","subj":"T11","obj":"D008133"},{"id":"A8","pred":"#label","subj":"T8","obj":"D007008"},{"id":"A9","pred":"#label","subj":"T9","obj":"DISEASE"},{"id":"A7","pred":"#label","subj":"T7","obj":"D016171"},{"id":"A4","pred":"#label","subj":"T4","obj":"DISEASE"},{"id":"A1","pred":"#label","subj":"T1","obj":"D008133"},{"id":"A6","pred":"#label","subj":"T6","obj":"DISEASE"},{"id":"A3","pred":"#label","subj":"T3","obj":"DISEASE"},{"id":"A2","pred":"#label","subj":"T2","obj":"D008133"},{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":106,"end":114},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":647,"end":655},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":734,"end":742},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":1080,"end":1088},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":1212,"end":1220},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":1662,"end":1670},"obj":"OrganismTaxon"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":64,"end":73},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":211,"end":220},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":356,"end":365},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":593,"end":602},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":627,"end":636},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":753,"end":762},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":876,"end":885},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":902,"end":911},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":1058,"end":1067},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":1235,"end":1244},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":1338,"end":1347},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1497,"end":1506},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":1513,"end":1529},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1640,"end":1649},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":1733,"end":1742},"obj":"ChemicalEntity"},{"id":"T30","span":{"begin":1761,"end":1777},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":1794,"end":1803},"obj":"ChemicalEntity"},{"id":"T33","span":{"begin":1906,"end":1915},"obj":"ChemicalEntity"}],"attributes":[{"id":"A21","pred":"ID:","subj":"T21","obj":"D008691"},{"id":"A22","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D008691"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D008691"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D008691"},{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A19","pred":"ID:","subj":"T19","obj":"D008691"},{"id":"A20","pred":"ID:","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A28","pred":"ID:","subj":"T28","obj":"D008691"},{"id":"A29","pred":"ID:","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A33","pred":"ID:","subj":"T33","obj":"D008691"},{"id":"A34","pred":"ID:","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D008691"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A31","pred":"ID:","subj":"T31","obj":"D011188"},{"id":"A32","pred":"ID:","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_26216"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D008691"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A25","pred":"ID:","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_38559"},{"id":"A26","pred":"ID:","subj":"T26","obj":"D008691"},{"id":"A27","pred":"ID:","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A15","pred":"ID:","subj":"T15","obj":"D008691"},{"id":"A16","pred":"ID:","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D008691"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A30","pred":"ID:","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_38559"},{"id":"A17","pred":"ID:","subj":"T17","obj":"D008691"},{"id":"A18","pred":"ID:","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A23","pred":"ID:","subj":"T23","obj":"D008691"},{"id":"A24","pred":"ID:","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D008691"},{"id":"A10","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T33","span":{"begin":1906,"end":1915},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":1794,"end":1803},"obj":"ChemicalEntity"},{"id":"T30","span":{"begin":1761,"end":1777},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":1733,"end":1742},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1640,"end":1649},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":1513,"end":1529},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1497,"end":1506},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":1338,"end":1347},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":1235,"end":1244},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":1058,"end":1067},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":902,"end":911},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":876,"end":885},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":753,"end":762},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":627,"end":636},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":593,"end":602},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":356,"end":365},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":211,"end":220},"obj":"ChemicalEntity"},{"id":"T1","span":{"begin":64,"end":73},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":1761,"end":1777},"obj":"GeneOrGeneProduct"},{"id":"T77348","span":{"begin":1513,"end":1529},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":1369,"end":1373},"obj":"GeneOrGeneProduct"},{"id":"T62344","span":{"begin":683,"end":689},"obj":"GeneOrGeneProduct"},{"id":"T60521","span":{"begin":1861,"end":1877},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1844,"end":1859},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T19616","span":{"begin":1612,"end":1636},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1558,"end":1569},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28034","span":{"begin":1261,"end":1280},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1108,"end":1124},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T418","span":{"begin":1022,"end":1037},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T66972","span":{"begin":326,"end":350},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T71138","span":{"begin":221,"end":245},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28259","span":{"begin":158,"end":174},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T27970","span":{"begin":13,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8982","span":{"begin":1662,"end":1670},"obj":"OrganismTaxon"},{"id":"T88625","span":{"begin":1212,"end":1220},"obj":"OrganismTaxon"},{"id":"T34022","span":{"begin":1080,"end":1088},"obj":"OrganismTaxon"},{"id":"T88880","span":{"begin":734,"end":742},"obj":"OrganismTaxon"},{"id":"T1479","span":{"begin":647,"end":655},"obj":"OrganismTaxon"},{"id":"T4697","span":{"begin":106,"end":114},"obj":"OrganismTaxon"}],"attributes":[{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D008691"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D008691"},{"id":"A47955","pred":"#label","subj":"T8","obj":"D007008"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D008691"},{"id":"A56117","pred":"#label","subj":"T66972","obj":"DISEASE"},{"id":"A10","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D008691"},{"id":"A44895","pred":"#label","subj":"T6","obj":"DISEASE"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D008691"},{"id":"A25","pred":"ID:","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_38559"},{"id":"A34564","pred":"#label","subj":"T71138","obj":"DISEASE"},{"id":"A34","pred":"ID:","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A33","pred":"ID:","subj":"T33","obj":"D008691"},{"id":"A18504","pred":"#label","subj":"T28259","obj":"D008133"},{"id":"A50693","pred":"#label","subj":"T10","obj":"DISEASE"},{"id":"A24","pred":"ID:","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A23","pred":"ID:","subj":"T23","obj":"D008691"},{"id":"A28540","pred":"#label","subj":"T27970","obj":"D008133"},{"id":"A29","pred":"ID:","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A28","pred":"ID:","subj":"T28","obj":"D008691"},{"id":"A18","pred":"ID:","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A17","pred":"ID:","subj":"T17","obj":"D008691"},{"id":"A22","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A21","pred":"ID:","subj":"T21","obj":"D008691"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D008691"},{"id":"A20","pred":"ID:","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A19","pred":"ID:","subj":"T19","obj":"D008691"},{"id":"A32","pred":"ID:","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_26216"},{"id":"A31","pred":"ID:","subj":"T31","obj":"D011188"},{"id":"A53790","pred":"#label","subj":"T28034","obj":"D016171"},{"id":"A83257","pred":"#label","subj":"T418","obj":"DISEASE"},{"id":"A63749","pred":"#label","subj":"T60521","obj":"D008133"},{"id":"A30","pred":"ID:","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_38559"},{"id":"A14","pred":"ID:","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D008691"},{"id":"A82813","pred":"#label","subj":"T19616","obj":"DISEASE"},{"id":"A27","pred":"ID:","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A26","pred":"ID:","subj":"T26","obj":"D008691"},{"id":"A16","pred":"ID:","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_6807"},{"id":"A15","pred":"ID:","subj":"T15","obj":"D008691"}],"text":"Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\nBACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction. Methadone prolongs the QT interval in vitro in a dose-dependent manner. In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.\nMETHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital. A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone. In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.\nRESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects. Six patients (3.6%) in the methadone group presented torsades de pointes. QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P\u003c.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.\nCONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation. Long QT syndrome can occur with low doses of methadone."}